Clonazolam Stats & Data

Clonazolam was first synthesized in 1971 by The Upjohn Company, the pharmaceutical corporation that would later bring alprazolam (Xanax) to market. In the original research, the compound was described as the most active substance in the series of triazolobenzodiazepines tested. Despite this notable potency and coverage by patents, the drug was never developed for clinical use or marketed. The compound remained largely obscure until reports of its use as a research chemical began appearing online around 2013, making it one of the more recently emerged designer benzodiazepines. The European Monitoring Centre for Drugs and Drug Addiction was first notified of clonazolam's presence in the European Union in January 2015, following a report from Sweden. By 2016, detection of novel benzodiazepines had risen markedly across Europe, with over 300,000 tablets containing designer benzodiazepines—including clonazolam, diclazepam, etizolam, and flubromazolam—seized in 2015, nearly double the figure from the previous year. Clonazolam's extreme potency has made it a subject of particular concern within online drug communities. Early forum discussions frequently noted incidents of blackouts and the rapid development of dependence, establishing a reputation that distinguished it from other designer benzodiazepines in circulation. Its microgram-range activity led to distribution methods uncommon for benzodiazepines, with the substance appearing on blotter paper and in volumetrically prepared solutions rather than as raw powder.

Forked from Subjective Effect Documentation by Josie Kins, September 2015. Via dose.wiki (CC0).

Clonazolam likely has a low toxicity relative to dose. However, it is potentially lethal when mixed with depressants like alcohol or opioids. It is strongly recommended that one use harm reduction practices, such as volumetric dosing, when using this substance to ensure the accurate administration of the intended dose.

Effects aggregated from 16 experience reports (16 single-substance Erowid)

Each bar is the share of reports mentioning the effect; its whisker, and the band on the rows below, is the 95% interval: where the share could plausibly be with other reports of the same kind.

Too few reports for bars: these effects come from 16 single-substance Erowid reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

Also reported in combinations. In the 12 Clonazolam reports where another drug was taken too, 2 mention hospital, emergency services or an overdose, 0 a seizure and 1 psychosis (too few reports for percentages). In the 16 single-substance reports: 4, 2 and 0. These are not in the figures above: they cannot be put down to Clonazolam alone, and a mention is not always something that happened to the writer.

Dose distribution from experience reports, one dose per report (the first listed). Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route: most are real heavy doses or overdoses, not mistakes.

From 59 of 63 recorded dose entries: those that state a weight (mg, g or µg), in routes with at least five of them. Values above Q3 + 3×IQR, far above what people typically take, are left out; they can include real heavy doses and overdoses, not only mistakes.

Most co-occurring substances, as a share of all 28 reports filed under Clonazolam; whiskers are 95% intervals

Most common forms and preparations, as a share of the 19 reports that give one

Too few reports for bars: these forms come from 19 reports, and a bar is drawn only from 20 reports or more. With fewer, a percentage cannot tell a common effect from a rare one. Counts are shown instead. Why 20?

• Pill / Tablet 9 of 19
• Liquid 6 of 19
• Powder / Crystals 3 of 19

Dose per kg of body weight, one dose per report (the first listed), from reports giving a weight of 30–250 kg. Doses above Q3 + 3×IQR, far above what people typically take, are left out of the median and range and listed under each route.

Redosing behavior across 23 reports